Hims & Hers to partner with Novo Nordisk and stop selling compounded GLP-1s

Telehealth company Hims & Hers on Monday announced a “strategic shift” in its business model, partnering with pharmaceutical company Novo Nordisk to sell its blockbuster GLP-1 medication and stop selling the “copycat” compounded versions it has long advertised. In a press release, Hims & Hers said it will “no longer advertise compounded GLP-1 offerings on…

Hims & Hers to partner with Novo Nordisk and stop selling compounded GLP-1s

Tracking mysteries of loss of Y chromosome, cancer

FDA approves Wellcovorin for ultra-rare disease. The Trump admin touted it as a treatment for autism

FDA approves Wellcovorin for ultra-rare disease. The Trump admin touted it as a treatment for autism

How to untangle ethics of psychedelics for therapeutic care

Novel therapy reduces depression in family caregivers

The Benefits of Joining a Fitness Group

Planned Parenthood to spend $40m to boost Biden, Democrats ahead of November

Biden administration suspends funding for scientist at center of COVID lab leak theory

Novel teamwork, promising results for glioblastoma treatment

‘Harvard Thinking’: Facing death with dignity

Asking the internet about birth control

FDA panel recommends mRNA flu vaccine for older adults

Ebola outbreak zone cases up almost 40 percent in a week

Cancer patients are choosing ivermectin over chemo, and doctors are concerned

Senate Dems launch investigation into RFK Jr. vaccine panel changes

Recent News

FDA panel recommends mRNA flu vaccine for older adults

Ebola outbreak zone cases up almost 40 percent in a week

Cancer patients are choosing ivermectin over chemo, and doctors are concerned

Senate Dems launch investigation into RFK Jr. vaccine panel changes

Recent News

FDA panel recommends mRNA flu vaccine for older adults

Ebola outbreak zone cases up almost 40 percent in a week

Popular News

About Health Land Corporation